NextCure Completes $21.5 Million PIPE Financing Round
Private Placement Announcement: NextCure has successfully closed a private placement in public equity, raising approximately $21.5 million, led by Ikarian Capital and other healthcare-focused funds.
Details of the Offering: The company issued 708,428 shares of common stock at $8.52 per share and pre-funded warrants for 1,815,049 shares at $8.519 each, exempt from registration under the Securities Act of 1933.
Use of Proceeds: NextCure plans to utilize the net proceeds for general working capital, extending its cash runway into the first half of 2027, beyond the initial target of 2026.
Future Developments: The funding will support upcoming proof of concept data readouts for NextCure's two antibody drug conjugate programs, SIM0505 and LNCB74.
Trade with 70% Backtested Accuracy
Analyst Views on NXTC
About NXTC
About the author
NextCure Completes $21.5 Million PIPE Financing Ahead of Phase 1 POC Data Releases in Early 2026
Funding Announcement: NextCure, Inc. has successfully closed a private placement of common stock, raising approximately $21.5 million, which will extend its cash runway into the first half of 2027.
Use of Proceeds: The funds will be utilized for general working capital and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74.
Private Placement Details: The offering involved the sale of 708,428 shares of common stock at $8.52 per share, along with pre-funded warrants for additional shares, all conducted under an exemption from the registration requirements of the Securities Act.
Company Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly targeting patients who do not respond to existing treatments.
NextCure Stock Rises 15% Following Private Placement News
Stock Performance: NextCure, Inc. (NXTC) shares rose 14.88% to $9.61 following the announcement of a private placement of approximately $21.5 million.
Funding Details: The company will issue 2,523,477 shares at $8.52 per share to institutional investors, with the funding expected to close around November 13, 2025.
Cash Runway Extension: The new funding will extend NextCure's cash runway into the first half of 2027 and support its antibody-drug-conjugate programs targeting CDH6 and B7-H4.
Trading Activity: The announcement led to unusually heavy trading volume for NXTC, with its stock price fluctuating between $2.65 and $9.61 over the past year.
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
Market Overview: U.S. stock futures showed mixed performance following a volatile trading session, with President Trump pressuring the Federal Reserve for interest rate cuts ahead of their upcoming decision on July 30. Analysts noted a bullish divergence in market breadth despite recent declines in certain sectors.
Company Highlights: Alphabet Inc. reported strong quarterly results while Tesla's performance fell short of expectations. Notable stock movements included Intel's significant drop after announcing layoffs, and several companies like NextCure and Linkhome Holdings saw substantial gains due to positive developments or IPOs.
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Deckers Outdoor Corporation Performance: Shares of Deckers Outdoor Corporation rose 11.6% in pre-market trading after reporting first-quarter earnings of 93 cents per share, exceeding analyst estimates, and quarterly revenue of $964.5 million, surpassing expectations.
Market Movements: Various stocks experienced significant changes in pre-market trading, with notable gainers including Linkhome Holdings (up 51%) and Coursera (up 22.5%), while losers included Incannex Healthcare (down 42.1%) and Intel Corporation (down 5.9%).
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
NextCure's Stock Surge: Shares of NextCure Inc. rose nearly 30% to $6.60 in premarket trading after positive preclinical results for its drug candidate NC605, aimed at treating brittle bone disease (osteogenesis imperfecta).
Drug Candidate Progress: NC605, an anti-Siglec-15 antibody, demonstrated improved bone microarchitecture and reduced fractures in a mouse model, with plans for an Investigational New Drug submission within 12 to 18 months, contingent on securing financial support.
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
Stock Surge: NextCure Inc.'s stock rose by 44.87% to $7.62 after presenting promising preclinical data for NC605, a potential treatment for brittle bone disease, which showed improved bone microarchitecture and reduced fracture incidence.
Strategic Developments: The company has also formed a strategic partnership with Simcere Zaiming to develop a new antibody-drug conjugate for solid tumors, indicating ongoing advancements in its research and development efforts despite recent stock volatility.
NextCure Completes $21.5 Million PIPE Financing Ahead of Phase 1 POC Data Releases in Early 2026
Funding Announcement: NextCure, Inc. has successfully closed a private placement of common stock, raising approximately $21.5 million, which will extend its cash runway into the first half of 2027.
Use of Proceeds: The funds will be utilized for general working capital and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74.
Private Placement Details: The offering involved the sale of 708,428 shares of common stock at $8.52 per share, along with pre-funded warrants for additional shares, all conducted under an exemption from the registration requirements of the Securities Act.
Company Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly targeting patients who do not respond to existing treatments.
NextCure Stock Rises 15% Following Private Placement News
Stock Performance: NextCure, Inc. (NXTC) shares rose 14.88% to $9.61 following the announcement of a private placement of approximately $21.5 million.
Funding Details: The company will issue 2,523,477 shares at $8.52 per share to institutional investors, with the funding expected to close around November 13, 2025.
Cash Runway Extension: The new funding will extend NextCure's cash runway into the first half of 2027 and support its antibody-drug-conjugate programs targeting CDH6 and B7-H4.
Trading Activity: The announcement led to unusually heavy trading volume for NXTC, with its stock price fluctuating between $2.65 and $9.61 over the past year.
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
Market Overview: U.S. stock futures showed mixed performance following a volatile trading session, with President Trump pressuring the Federal Reserve for interest rate cuts ahead of their upcoming decision on July 30. Analysts noted a bullish divergence in market breadth despite recent declines in certain sectors.
Company Highlights: Alphabet Inc. reported strong quarterly results while Tesla's performance fell short of expectations. Notable stock movements included Intel's significant drop after announcing layoffs, and several companies like NextCure and Linkhome Holdings saw substantial gains due to positive developments or IPOs.
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Deckers Outdoor Corporation Performance: Shares of Deckers Outdoor Corporation rose 11.6% in pre-market trading after reporting first-quarter earnings of 93 cents per share, exceeding analyst estimates, and quarterly revenue of $964.5 million, surpassing expectations.
Market Movements: Various stocks experienced significant changes in pre-market trading, with notable gainers including Linkhome Holdings (up 51%) and Coursera (up 22.5%), while losers included Incannex Healthcare (down 42.1%) and Intel Corporation (down 5.9%).
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
NextCure's Stock Surge: Shares of NextCure Inc. rose nearly 30% to $6.60 in premarket trading after positive preclinical results for its drug candidate NC605, aimed at treating brittle bone disease (osteogenesis imperfecta).
Drug Candidate Progress: NC605, an anti-Siglec-15 antibody, demonstrated improved bone microarchitecture and reduced fractures in a mouse model, with plans for an Investigational New Drug submission within 12 to 18 months, contingent on securing financial support.
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
Stock Surge: NextCure Inc.'s stock rose by 44.87% to $7.62 after presenting promising preclinical data for NC605, a potential treatment for brittle bone disease, which showed improved bone microarchitecture and reduced fracture incidence.
Strategic Developments: The company has also formed a strategic partnership with Simcere Zaiming to develop a new antibody-drug conjugate for solid tumors, indicating ongoing advancements in its research and development efforts despite recent stock volatility.
